Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Max Bayer

Pharma Reporter

Infectious disease professionals, bracing for an overhaul of the CDC’s vaccine advisory group, are in discussions to stand up a parallel committee of experts outside …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Marks’ exit at FDA rattles an already teetering biotech industry

Lilly's heart disease drug could be dosed as little as once a year, study shows

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025

What’s next after Marks? At FDA, questions over more top exits and future vision for drug agency

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows

In­spir­na, which was prepar­ing for a Phase 3 can­cer tri­al, has fold­ed

Al­pha­bet’s Iso­mor­phic Labs rais­es $600M in biotech’s largest round of 2025

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Marks’ exit at FDA rattles an already teetering biotech industry

Lilly's heart disease drug could be dosed as little as once a year, study shows

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025

What’s next after Marks? At FDA, questions over more top exits and future vision for drug agency

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO